Abstract

Potential Factors That Impact Lenalidomide/R-CHOP Efficacy in Previously Untreated Diffuse Large B-Cell Lymphoma in the ROBUST and ECOG-ACRIN 1412 Studies

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Quality of Life Was Not Negatively Impacted By the Addition of Lenalidomide to R-CHOP Chemotherapy (R2-CHOP) Compared with Placebo Plus R-CHOP Chemotherapy in Patients with Previously Untreated Activated B-Cell (ABC)-Type Diffuse Large B-Cell Lymphoma (DLBCL): Health-Related Quality of Life (HRQoL) Analysis of the International Robust Study
Wojciech Jurczak ... Kazuhito Yamamoto
Blood | VOL. 134
Wojciech Jurczak, et. al.Wojciech Jurczak ... Kazuhito Yamamoto
13 Nov 2019
Efficacy and Safety of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Anastasios Stathis ... John A Radford
Blood | VOL. 136
Anastasios Stathis, et. al.Anastasios Stathis ... John A Radford
05 Nov 2020
Worldwide Examination of Patients with CLL Hospitalized for COVID-19
... Massimo Gentile
Blood | VOL. 136
, et. al. ... Massimo Gentile
05 Nov 2020
Updated Report on Identification of Molecular Predictors of Tazemetostat Response in an Ongoing NHL Phase 2 Study
Alicia Clawson ... Christophe Fruchart
Blood | VOL. 132
Alicia Clawson, et. al.Alicia Clawson ... Christophe Fruchart
29 Nov 2018
View more papers

More From: Blood

Paper Title
Journal
Date
Author
Clinical networking results in continuous improvement of the outcome of patients with acute promyelocytic leukemia.
Luisa Corrêa De Araujo Koury ... Eduardo M Rego
Blood | VOL. -
Luisa Corrêa De Araujo Koury, et. al.Luisa Corrêa De Araujo Koury ... Eduardo M Rego
28 May 2024
Adaptation to ex vivo culture reduces human hematopoietic stem cell activity independently of cell cycle.
Carys S Johnson ... Elisa Laurenti
Blood | VOL. -
Carys S Johnson, et. al.Carys S Johnson ... Elisa Laurenti
28 May 2024
CD20-bispecific antibodies improve response to CD19-CAR T-cells in lymphoma in-vitro and CLL in-vivo models.
Berit J Brinkmann ... Sascha Dietrich
Blood | VOL. -
Berit J Brinkmann, et. al.Berit J Brinkmann ... Sascha Dietrich
28 May 2024
Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37+ lymphoid malignancies
Matthew J Frigault ... Marcela V Maus
Blood | VOL. -
Matthew J Frigault, et. al.Matthew J Frigault ... Marcela V Maus
23 May 2024
View more papers